Drug delivery system innovation and Health Technology Assessment: Upgrading from Clinical to Technological Assessment

International Journal of Pharmaceutics

Volumn 495, Issue 2, 2015, Pages 1005-1018

  Panzitta, Michele ^a,b   Bruno, Giorgio ^b,c   Giovagnoli, Stefano ^a   Mendicino, Francesca R ^a   Ricci, Maurizio ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b AFI Associazione Farmaceutici dell'Industria   (Italy)

^c Recipharm AB   (Italy)

Author keywords

Clinical pharmaceutics; Drug delivery systems; Health Technology Assessment; Nanoparticles; Pharmaceutics; Quality by design; Quality risk management

Indexed keywords

EXCIPIENT; NANOCARRIER; NANOPARTICLE; PACLITAXEL; SOLVENT;

ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); COMMERCIAL PHENOMENA; CONTRACT; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG MANUFACTURE; DRUG MARKETING; DRUG QUALITY; DRUG SAFETY; DRUG SOLUBILITY; EVIDENCE BASED MEDICINE; HEALTH TECHNOLOGY ASSESSMENT; HUMAN; KNOWLEDGE; MEDICAL TECHNOLOGY; METHODOLOGY; PHYSICAL CHEMISTRY; PRACTICE GUIDELINE; PREFORMULATION; PRIORITY JOURNAL; PROCESS CONTROL; PROCESS DESIGN; PROCESS DEVELOPMENT; PRODUCT DEVELOPMENT; REIMBURSEMENT; RISK MANAGEMENT; SKILL; SUSTAINABLE DEVELOPMENT; BIOMEDICAL TECHNOLOGY ASSESSMENT; PROFESSIONAL COMPETENCE; STANDARDS;

BIOMEDICAL TECHNOLOGY; DRUG DELIVERY SYSTEMS; EVIDENCE-BASED MEDICINE; HUMANS; PROFESSIONAL COMPETENCE; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 84944044786     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2015.09.026     Document Type: Article

References (71)

1. AIFA, 2014a. http://www.agenziafarmaco.gov.it/it/content/carenze-dei-medicinali.
2. AIFA, 2014b. http://www.agenziafarmaco.gov.it/sites/default/files/elenco-medicinali-carenti-11082014.pdf, (accessed on 14.09.14.).
3. A.C. Anselmo, and S. Mitragotri An overview of clinical and commercial impact of drug delivery systems J. Control. Release 190 2014 15 28
4. A. T. Kearney, 2014. Pharma Supply Chain Panel.
5. ® - the first FDA-approved nano-drug: lessons learned J. Control. Release 160 2012 117 134 10.1016/j.jconrel.2012.03.020
6. G.S. Banker, and C.T. Rhodes Modern Pharmaceutics fourth ed. 2002 Marcel Dekker
7. S. Benita Microencapsulation: Methods and Industrial Applications second ed. 2005 Taylor and Francis group
8. N. Bertrand, J. Wu, X. Xu, N. Kamaly, and O.C. Farokhzad Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology Adv. Drug Deliv. Rev. 66 2014 2 25
9. D. Brambilla, P. Luciani, and J.C. Leroux Breakthrough discoveries in DD technologies: the next 30 years J. Control. Release 190 2014 9 14
10. E. Breuer, M.S. Chorghade, J. Fisher, and G. Golomb Glossary of terms related to pharmaceutics (IUPAC recommendations 2009) Pure Appl. Chem. 81 5 2009 971 999 10.1351/PAC-REC-04-10-14
11. N. Desai Challenges in development of nanoparticle-based therapeutics AAPS J. Vol. 14 2 2012
12. M.F. Drummond, J. Sanford Schwartz, B. Jönsson, B.R. Luce, P.J. Neumann, U. Siebert, and S.D. Sullivan Key principles for the improved conduct of health technology assessments for resource allocation decisions Int. J. Technol. Assess. Health Care 24 3 2008 1 15
13. M.F. Drummond, M.J. Sculper, G.W. Torrance, B.J. O'Brien, and G.L. Stoddart metodi per la valutazione economica dei programmi sanitari, terza edizione 2010 Il Pensiero Scientifico Editore
14. R. Duncan Polymer therapeutics: top 10 selling pharmaceuticals - what next? J. Control. Release 190 2014 371 380
15. D. Eddy HTA and evidence-based medicine: what are we talking about? Valuein Health 12 2 2009 S6 S7
16. EMA, 2012. Reflection paper on the pharmaceutical development of intravenous medicinal products containing active substances solubilised in micellar systems, EMA/CHMP/QWP/799402/2011 March 2012.
17. EMA, 2013a. Reflection paper on the data requirements for intravenous liposomal products developed with reference to an innovator liposomal product, EMA/CHMP/806058/2009/Rev. 02 February 2013
18. EMA, 2013b. Annual Report from the SME Office 2012, EMA/801597/2012 February 2013.
19. EMA, 2013c. Reflection paper on the data requirements for intravenous iron-based nano-colloidal products developed with reference to an innovator medicinal product DRAFT, EMA/CHMP/SWP/620008/2012 July 2013.
20. EMA, 2013d. Joint MHLW/EMA reflection paper on the development of block copolymer micelle medicinal products, EMA/CHMP/13099/2013 December 2013.
21. EMA, 2014a. Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities, EMA/CHMP/CVMP/SWP/169430/2012 November 2014.
22. EMA, 2014b. http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document-listing/document-listing-000376.jsp&mid=WC0b01ac05807477a6, (accessed on 22.06.14.).
23. EMEA, 1998. EMEA, note for guidance on maximum shelf life for sterile products for human use after first opening or following reconstitution, CPMP/QWP/159/96 corr January 1998.
24. EMEA, 2001. EMEA, note for guidance on in-use stability testing of human medicinal products, CPMP/QWP/2934/99 March 2001.
25. EMEA, 2005. EMEA, Guideline On Plastic Immediate Packaging Materials, CPMP/QWP/4359/03 - CVMP/205/04 May 2005.
26. EMEA ICH Q5C, 1996. Topic Q 5C Quality of Biotechnological Products: Stability Testing of Biotechnological/Biological Products, CPMP/ICH/138/95 July 1996.
27. EMA ICH Q1A, 2003. EMA, ICH Topic Q 1 A (R2) Stability Testing of new Drug Substances and Products, CPMP/ICH/2736/99 August 2003.
28. EMA ICH Q5E, 2005. Topic Q 5 E Comparability of Biotechnological/Biological Products, CPMP/ICH/5721/03 June 2005.
29. Eudralex GMP, a. EU Guidelines for Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use, Eudralex Vol. 4 Annex 15: Qualification and Validation- DRAFT March 2015.
30. Eudralex GMP, b. EU Guidelines for Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use, Eudralex Part 1Chapter 3: Premises and Equipment, March 2015.
31. Eudralex GMP, c. EU Guidelines for Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use, EudraLex, Vol. 4, Chapter 1, revision 3 Pharmaceutical Quality System.
32. European Parliament, 2001a. DIRECTIVE 2001/20/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use.
33. European Parliament, 2001b. DIRECTIVE 2001/83/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 6 November 2001 on the Community code relating to medicinal products for human use, art 49.
34. European Parliament, 2001c. DIRECTIVE 2001/83/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 6 November 2001 on the Community code relating to medicinal products for human use, art 51.
35. European Technology Platform Nanomedicine, Contribution of Nanomedicine to Horizon 2020 - White Paper to the Horizon 2020 Framework Programme for Research and Innovation - Recommendations from the Nanomedicine Community, May 2013.
36. FDA, 2014a. https://www.federalregister.gov/regulations/0910-AG88/revision-of-postmarketing-reporting-requirements-discontinuance-or-interruption-in-supply-of-certain, (accessed on 22.06.14.).
37. FDA, 2014b. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM199635.pdf.
38. A.T. Florence An Introduction to Clinical Pharmaceutics 2010 Pharmaceutical press
39. A.T. Florence, and D. Attwood Physicochemical Principles of Pharmacy fourth ed. 2006 Pharmaceutical Press
40. P. Galvin, and et al. Nanoparticle-based drug delivery: case studies for cancer and cardiovascular applications Cell. Mol. Life Sci. 69 2012 389 404
41. M. Gibson Pharmaceutical Pre formulation and Formulation second ed. 2009 Informa Healthcare
42. ICH M4, 2002. the common technical document for the registration of pharmaceuticals for human use: Quality M4Q (R1), September 2002.
43. ICH Q9, 2005. Quality Risk Management Q9, November 2005.
44. ICH Q8, 2009. Pharmaceutical Development Q8(R2), August 2009.
45. ICH Q3C, 2013. impurities: guideline for residual solvents Q3C (R5), February 2013.
46. INAHTA. www.inahta.org.
47. ISPOR. https://www.ispor.org/Terminology/Default.asp, (accessed on 09.05.15.).
48. Jaeschke, R., Guyatt, G.H., 1999. What is evidence based medicine? Seminar in Medical Practice Turner White Communication Inc. Vol. 2, No. 3, October 1999.
49. Joint Commission, 2013. Joint Commission International Accreditation Standards for Hospitals-5th edition standards only version 2013.
50. J. Kreuter Colloidal Drug Delivery Systems 1994 Marcel Dekker Inc. (Chapter 5. II)
51. R. Krishna, and L. Yu Biopharmaceutics Applications in Drug Development 2008 Springer
52. M. Martinez, M. Rathbone, D. Burgess, and M. Huynh In vitro and in vivo considerations associated with parenteral sustained releaseproducts: a review based upon information presented and points 2007 Controlled Release Society Annual Meeting J. Control. Release 129 2008 79 87
53. M. Martinez, M. Rathbone, D. Burgess, and M. Huynh Breakout session summary from AAPS/CRS joint workshop on critical variables in the in vitro and in vivo performance of parenteral sustained release products J. Control. Release 142 2010 2 7
54. MIN SAL, 2003. Ministero Della Salute Italiano-Risk Management in sanità: il problema degli errori-Commissione tecnica sul rischio clinico- D. M. 5 marzo 2003.
55. MIN SAL, 2006. Ministero Della Salute Italiano- La Sicurezza dei Pazienti e la gestione del rischio clinico- Luglio 2006.
56. S. Mollá-Cantavella, and et al. Intravenous meropenem stability in physiological saline at room temperature Eur. J. Hosp. Pharm. 21 2014 202 207 10.1136/ejhpharm-2013-000430
57. P. O'Neill, and N.J. Devlin An Analysis of NICE's 'Restricted'(or 'Optimized') Decisions Pharmacoeconomics 28 11 2010 987 993
58. Panzitta, M., 2015. Economic sustainability for therapeutic innovation and pharmaceutical industry activities: aims of AFI study group on pharmaceutical economy -55°Simposio AFI-Abstract.
59. Panzitta, M., D'Arpino, A., 2013. Il valore terapeutico ed economico delle caratteristiche formulative e tecnologiche: come può misurare l'innovazione il farmacista ospedaliero, 53°Symposium AFI 2013-Abstract.
60. Panzitta, M., Ricci, M., 2014. Farmacoeconomia e cronoterapia, 54°Symposium AFI 2014-Abstract.
61. Panzitta, M., et al., 2013. Sperimentazioni cliniche: il ruolo del farmacista ospedaliero, Notiziario Chimico Farmaceutico-Giugno 2013.
62. PICS, 2012. P Harmaceutical Inspection Convention-pharmaceutical Inspection Co-operation ScheME; aide memory: Assessment Of Quality Risk Management Implementation; PI 038-1 26 March 2012.
63. D. Sackett, and et al. Evidence Based Medicine: what it is and what it isn't Br. Med. J. 1996 13
64. H. Schreier Drug Targeting Technology 2001 Marcel Dekker
65. L. Shargel, S. Eu-Pong, and A.B.C. Yu Applied Biopharmaceutics and Pharmacokinetics fifth ed. 2005 McGraw-Hill
66. V.J. Venditto, and F.C. Szoka Jr. Cancer nanomedicines: so many papers and so few drugs! Adv. Drug Deliv Rev. 65 January (1) 2013 80 88 10.1016/j.addr.2012.09.038
67. L. Wu, J. Zhang, and W. Watanabe Physical and chemical stability of drug nanoparticles Adv. Drug Deliv. Rev. 63 2011 456 469
68. X. Xu, M.A. Khan, and D.J. Burgess Int. J. Pharm. 419 2011 52 59
69. F. Yerlikaya, A. Ozgen, I. Vural, O. Guven, E. Karaagaoglu, M.A. Khan, and Y. Capan Development and evaluation of paclitaxel nanoparticles using a quality-by-design approach J. Pharm. Sci. 102 2013 3748 3761
70. L.X. Yu Pharm. Res. vol. 25 April (4) 2008
71. D. Zucker, A.V. Andriyanov, A. Steiner, U. Raviv, and Y. Barenholz Characterization of PEGylated nanoliposomes co-remotely loaded with topotecan and vincristine: relating structure and pharmacokinetics to therapeutic efficacy J. Control. Release 160 2012 281 289